Table 3.
Results from in vitro EDTA transchelation stability assays.*
| Starting complex | Ligand challenge | pH | % Intact starting species by incubation time | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Initial | 1 h | 3 h | 1 d | 3 d | 5 d | 7 d | |||
| 89Zr(DFO2) | 100 fold excess EDTA | 8.0 | 100 | 100 | 100 | 99.9 ± 0.1 | 94.3 ± 2.2 | 88.6 ± 2.8 | 81.4 ± 1.4 |
| 7.5 | 100 | 100 | 100 | 100 | 98.9 ± 1.0 | 97.6 ± 1.2 | 95.0 ± 0.5 | ||
| 7.0 | 100 | 100 | 100 | 99.8 ± 0.1 | 98.7 ± 0.3 | 92.5 ± 6.4 | 85.3 ± 2.7 | ||
| 6.5 | 100 | 100 | 99.5 ± 0.2 | 99.9 ± 0.2 | 98.0 ± 1.5 | 95.5 ± 1.9 | 90.4 ± 4.9 | ||
| 6 | 100 | 98.6 ± 0.4 | 96.6 ± 0.7 | 77.6 ± 2.9 | 42.1 ± 8.0 | 27.1 ± 8.1 | 20.6 ± 5.9 | ||
| 5.5 | 100 | 95.6 ± 1.0 | 90.2 ± 0.5 | 35.4 ± 1.1 | 7.0 ± 2.0 | 3.9 ± 1.8 | 1.5 ± 0.7 | ||
| 5.0 | 100 | 74.3 ± 0.9 | 43.9 ± 3.0 | 1.6 ± 0.1 | 1.0 ± 0.4 | 1.0 ± 0.6 | 0.6 ± 0.2 | ||
| 89Zr(DFO) | 100 fold excess EDTA | 8.0 | 98.1 ± 0.2 | 96.8 ± 1.3 | 97.5 ± 0.4 | 91.8 ± 1.3 | 75.9 ± 1.7 | 53.7 ± 1.4 | 33.6 ± 4.3 |
| 7.5 | 97.3 ± 0.6 | 96.6 ± 0.3 | 95.8 ± 0.5 | 84.9 ± 2.1 | 59.7 ± 5.5 | 36.5 ± 11.2 | 23.7 ± 9.6 | ||
| 7.0 | 96.2 ± 0.7 | 95.9 ± 0.7 | 95.5 ± 0.7 | 79.0 ± 1.6 | 50.2 ± 3.6 | 28.1 ± 8.1 | 16.1 ± 4.4 | ||
| 6.5 | 95.5 + 0.9 | 96.4 + 2.2 | 92.7 + 0.4 | 58.2 ± 3.6 | 21.6 + 1.5 | 11.6 + 0.7 | 8.5 + 1.4 | ||
| 6 | 99.3 + 0.2 | 94.9 + 0.2 | 84.6 + 2.2 | 20.4 ± 1.5 | 4.5 + 0.2 | 3.6 + 0.5 | 3.4 + 1.3 | ||
| 5.5 | 99.1 ± 0.2 | 89.6 ± 0.7 | 69.9 ± 1.5 | 5.3 ± 0.8 | 2.4 ± 0.3 | 2.7 ± 0.3 | 1.9 ± 0.1 | ||
| 5.0 | 97.0 ± 0.2 | 63.5 ± 1.3 | 27.3 ± 3.3 | 1.9 ± 0.7 | 1.1 ± 0.1 | 1.2 ± 0.1 | 1.1 + 0.0 | ||
| 100–99% | 98–90% | 89–80% | ≤ 79% | ||||||
Pre-radiolabeled [89Zr]Zr(DFO) and [89Zr]Zr(DFO2) complexes were mixed with a 100-fold molar excess of EDTA chelator at various pH values, and monitored by radio-iTLC for 7 days.